Literature DB >> 22783362

Chronic graft versus host disease with small bowel obstruction after unrelated hematopoietic stem cell transplantation in a patient with acute myeloid leukemia.

Ju Young Yoon1, Hyery Kim, Hyoung Jin Kang, Kyung Duk Park, Hee Young Shin, Hyo Seop Ahn.   

Abstract

Chronic graft versus host disease (GVHD) is a frequent complication after allogeneic hematopoietic stem cell transplantation (HSCT), but simultaneous small bowel obstruction is rare. Here, we report a child with acute myeloid leukemia who received an allogeneic HSCT from an unrelated matched donor. After HSCT, the patient developed severe chronic GVHD involving the small intestine, leading to obstruction of the terminal ileum. Small bowel resection was performed, and the symptoms improved without severe complications. Bowel obstruction should be considered as a possible complication of chronic GVHD; surgery may be a valuable corrective measure.

Entities:  

Keywords:  Acute myeloid leukemia; Graft versus host disease; Hematopoietic stem cell transplantation; Intestinal obstruction

Year:  2012        PMID: 22783362      PMCID: PMC3389064          DOI: 10.5045/kjh.2012.47.2.142

Source DB:  PubMed          Journal:  Korean J Hematol        ISSN: 1738-7949


  11 in total

1.  Surgery for intestinal graft-versus-host disease: report of two cases.

Authors:  J Evans; J Percy; R Eckstein; D Ma; M Schnitzler
Journal:  Dis Colon Rectum       Date:  1998-12       Impact factor: 4.585

Review 2.  Intestinal graft-versus-host disease: mechanisms and management.

Authors:  Hiroyuki Takatsuka; Tsuyoshi Iwasaki; Takahiro Okamoto; Eizo Kakishita
Journal:  Drugs       Date:  2003       Impact factor: 9.546

3.  Diffuse intestinal ulceration after marrow transplantation: a clinicopathologic study of 13 patients.

Authors:  G D Spencer; H M Shulman; D Myerson; E D Thomas; G B McDonald
Journal:  Hum Pathol       Date:  1986-06       Impact factor: 3.466

4.  Induction chemotherapy with idarubicin plus N4-behenoyl-1-beta-D-arabinofuranosylcytosine in acute myelogenous leukemia: a newly designed induction regimen--a prospective, cooperative multicenter study.

Authors:  H S Park; D W Kim; C C Kim; H K Kim; J S Kim; T J Hwang; H J Kim; H S Kim; H S Song; J W Park; H S Ahn; T J Chung; K S Cho; K S Lee; Y M Choi
Journal:  Semin Hematol       Date:  1996-10       Impact factor: 3.851

5.  Predictors of death from chronic graft-versus-host disease after bone marrow transplantation.

Authors:  J R Wingard; S Piantadosi; G B Vogelsang; E R Farmer; D A Jabs; L S Levin; W E Beschorner; R A Cahill; D F Miller; D Harrison
Journal:  Blood       Date:  1989-09       Impact factor: 22.113

Review 6.  Is severe intestinal chronic graft-versus-host disease an indication for surgery? A report of two cases.

Authors:  Andrée-Laure Herr; Jean-François Latulippe; Stéphane Carignan; Andrew Mitchell; Robert Bélanger; Jean Roy
Journal:  Transplantation       Date:  2004-05-27       Impact factor: 4.939

7.  Acute graft-versus-host disease of the intestine. A surgical perspective.

Authors:  G I McGregor; J D Shepherd; G L Phillips
Journal:  Am J Surg       Date:  1988-05       Impact factor: 2.565

Review 8.  GVHD pathophysiology: is acute different from chronic?

Authors:  Tomomi Toubai; Yaping Sun; Pavan Reddy
Journal:  Best Pract Res Clin Haematol       Date:  2008-06       Impact factor: 3.020

Review 9.  Diagnosis and manifestations of chronic graft-versus-host disease.

Authors:  Alexandra H Filipovich
Journal:  Best Pract Res Clin Haematol       Date:  2008-06       Impact factor: 3.020

10.  Obliterative enteritis complicating graft versus host disease.

Authors:  G Gavel; S Marven; M J Evans; J Walker; A J Vora
Journal:  Bone Marrow Transplant       Date:  2003-12       Impact factor: 5.483

View more
  1 in total

1.  Graft-versus-host disease complicated with small bowel obstruction in children: A case report.

Authors:  Yizhong Wang; Jiangbin Liu; Bingxin Jiang; Chenling Yuan; Licai Chen; Ting Zhang; Zhibao Lv
Journal:  Front Oncol       Date:  2022-09-08       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.